GPC3 Promotes Lung Squamous Cell Carcinoma Progression and HLA-A2-Restricted GPC3 Antigenic Peptide-Modified Dendritic Cell-Induced Cytotoxic T Lymphocytes to Kill Lung Squamous Cell Carcinoma Cells.
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
05
2023
revised:
01
09
2023
accepted:
29
09
2023
medline:
16
11
2023
pubmed:
15
11
2023
entrez:
15
11
2023
Statut:
epublish
Résumé
Lung squamous cell carcinoma (LUSC) is associated with poor clinical prognosis and lacks available targeted agents. GPC3 is upregulated in LUSC. Our study aimed to explore the roles of GPC3 in LUSC and the antitumor effects of HLA-A2-restricted GPC3 antigenic peptide-sensitized dendritic cell (DC)-induced cytotoxic T lymphocytes (CTLs) on LUSC. LUSC cells with GPC3 knockdown and overexpression were built using lentivirus packaging, and cell viability, clone formation, apoptosis, cycle, migration, and invasion were determined. Western blotting was used to detect the expression of cell cycle-related proteins and PI3K-AKT pathway-associated proteins. Subsequently, HLA-A2-restricted GPC3 antigenic peptides were predicted and synthesized by bioinformatic databases, and DCs were induced and cultured
Identifiants
pubmed: 37965271
doi: 10.1155/2023/5532617
pmc: PMC10643027
doi:
Substances chimiques
HLA-A2 Antigen
0
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Peptides
0
GPC3 protein, human
0
Glypicans
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5532617Informations de copyright
Copyright © 2023 Jing Ning et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Immunol Lett. 2020 Mar;219:46-53
pubmed: 31931024
Oncotarget. 2016 Jan 5;7(1):671-83
pubmed: 26621839
Sci Rep. 2018 Oct 26;8(1):15834
pubmed: 30367091
Br J Cancer. 2021 Jan;124(2):359-367
pubmed: 32929195
J Gene Med. 2019 Aug;21(8):e3099
pubmed: 31168873
Nat Commun. 2019 Aug 8;10(1):3578
pubmed: 31395880
Molecules. 2021 Aug 19;26(16):
pubmed: 34443624
Int Immunopharmacol. 2019 May;70:216-224
pubmed: 30851701
Front Oncol. 2021 Apr 13;11:628456
pubmed: 33928024
Annu Rev Pathol. 2021 Jan 24;16:223-249
pubmed: 33197221
J Immunol. 2018 Jan 15;200(2):443-449
pubmed: 29311386
Cancer Sci. 2019 Oct;110(10):3049-3060
pubmed: 31390678
Mol Cancer. 2021 Feb 5;20(1):28
pubmed: 33546704
Med Oncol. 2012 Jun;29(2):663-9
pubmed: 21556932
Nat Commun. 2020 Oct 21;11(1):5338
pubmed: 33087703
Science. 2018 Mar 23;359(6382):1355-1360
pubmed: 29567706
Discov Med. 2019 Mar;27(148):167-170
pubmed: 31095926
Cancer Sci. 2017 Oct;108(10):1947-1952
pubmed: 28749573
BMC Pulm Med. 2021 Jun 10;21(1):199
pubmed: 34112123
Oncol Lett. 2018 Jul;16(1):970-976
pubmed: 29963171
Am J Pathol. 2018 Sep;188(9):1973-1981
pubmed: 29935166
J Immunol. 2019 Feb 15;202(4):1045-1056
pubmed: 30617225
Hepatology. 2012 Oct;56(4):1380-90
pubmed: 22706665
Mol Ther. 2018 Feb 7;26(2):366-378
pubmed: 29339014
Biosci Rep. 2019 Jun 25;39(6):
pubmed: 31160489
Int J Mol Sci. 2020 Oct 02;21(19):
pubmed: 33023239
Annu Rev Immunol. 2013;31:563-604
pubmed: 23516985
Front Immunol. 2020 May 21;11:924
pubmed: 32508825
J Transl Med. 2018 Feb 6;16(1):23
pubmed: 29409514
J Anal Methods Chem. 2019 Mar 7;2019:1572526
pubmed: 30984441
Cell Mol Immunol. 2018 Apr;15(4):346-352
pubmed: 29563613
Front Oncol. 2019 Feb 26;9:108
pubmed: 30873384
Cancers (Basel). 2021 Jun 11;13(12):
pubmed: 34208113
Cancer Sci. 2019 Jul;110(7):2080-2089
pubmed: 31102428
Nanomedicine. 2019 Jan;15(1):164-174
pubmed: 30291897
BMJ. 2021 Nov 9;375:n2363
pubmed: 34753715
Genet Mol Res. 2015 Aug 28;14(3):10185-92
pubmed: 26345955
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Cancer Discov. 2021 Jan;11(1):OF3
pubmed: 33218972
Molecules. 2016 Jul 12;21(7):
pubmed: 27420038
J Hematol Oncol. 2021 Apr 28;14(1):71
pubmed: 33910591
Pharmaceutics. 2021 Jan 04;13(1):
pubmed: 33406722
Curr Pharm Des. 2016;22(37):5738-5751
pubmed: 27510476
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
Cancer Cell. 2019 Jun 10;35(6):901-915.e4
pubmed: 31185213
Cells. 2019 Aug 06;8(8):
pubmed: 31390757
Cells. 2019 Mar 31;8(4):
pubmed: 30935108
Front Oncol. 2021 Jan 11;10:530933
pubmed: 33505901
J Am Chem Soc. 2021 May 5;143(17):6470-6481
pubmed: 33881854
Mol Cancer. 2019 Mar 19;18(1):43
pubmed: 30890168
Front Endocrinol (Lausanne). 2017 Nov 10;8:311
pubmed: 29176962
Foods. 2021 Aug 29;10(9):
pubmed: 34574146
J Thorac Oncol. 2018 Feb;13(2):165-183
pubmed: 29175116
J Clin Oncol. 2014 Jan 10;32(2):121-8
pubmed: 24323028
Int J Mol Sci. 2021 Jun 28;22(13):
pubmed: 34203270
Cytotherapy. 2021 Sep;23(9):793-798
pubmed: 34215503
Nat Rev Immunol. 2021 Nov;21(11):718-738
pubmed: 33981085
Eur J Cancer. 2021 Nov;157:493-510
pubmed: 34561127
Acta Cytol. 2006 Jul-Aug;50(4):423-9
pubmed: 16901008
Cell Growth Differ. 1993 Feb;4(2):105-13
pubmed: 8494781
Cancer Sci. 2011 May;102(5):918-25
pubmed: 21281401
Proc Natl Acad Sci U S A. 2019 Jul 16;116(29):14620-14629
pubmed: 31262817
Surg Pathol Clin. 2020 Mar;13(1):17-33
pubmed: 32005431
Front Immunol. 2018 Dec 20;9:3059
pubmed: 30619378
Lung. 2020 Dec;198(6):897-907
pubmed: 33175991
Vaccines (Basel). 2021 Oct 01;9(10):
pubmed: 34696226
Cell Mol Immunol. 2021 Apr;18(4):842-859
pubmed: 33139907